Aerosolized interferon-alpha treatment in patients with multi-drug-resistant pulmonary tuberculosis

European Cytokine Network

Volumn 11, Issue 1, 2000, Pages 99-103

  Giosuè, Sandro ^a,c   Casarini, Massimo ^a   Ameglio, Franco ^b   Zangrilli, Profeta ^a   Palla, Massimiliano ^a   Altieri, Alfonso Maria ^a   Bisetti, Alberto ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAN GALLICANO DERMATOLOGICAL INSTITUTE   (Italy)

^c NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

Author keywords

Aerosolized IFN ; Cytokine; HRCT; MDR TB

Indexed keywords

ALPHA INTERFERON; AMIKACIN; AMINOSALICYLIC ACID; CD4 ANTIGEN; CIPROFLOXACIN; ETHAMBUTOL; ETHIONAMIDE; GAMMA INTERFERON; ISONIAZID; PYRAZINAMIDE; RIFABUTIN; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ADULT; AEROSOL; ARTICLE; BACTERIAL COUNT; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFICACY; FEMALE; FOLLOW UP; HELPER CELL; HUMAN; LUNG TUBERCULOSIS; MACROPHAGE; MALE; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; SPUTUM ANALYSIS; THORAX RADIOGRAPHY; TUBERCULOSIS CONTROL;

ADULT; AEROSOLS; ANTITUBERCULAR AGENTS; BRONCHOALVEOLAR LAVAGE FLUID; DRUG RESISTANCE, MULTIPLE; FEMALE; HUMANS; INTERFERON-ALPHA; INTERLEUKINS; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; SPUTUM; TUBERCULOSIS, PULMONARY; TUMOR NECROSIS FACTOR-ALPHA;

ACTINOBACTERIA (CLASS); BACTERIA (MICROORGANISMS); MYCOBACTERIUM; MYCOBACTERIUM TUBERCULOSIS; UNCULTURED ACTINOMYCETE;

EID: 0034101659     PISSN: 11485493     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. 1. Bloch A B, Cauthen G M, Onorato I M, Dansbury K G, Kelly G D, Driver C R, Snider D E Jr. 1994. Nationwide survey of drug-resistant tuberculosis in the United States. JAMA 271: 665.
2. 2. Iseman M D, Madsen L A. 1989. Drug-resistant tuberculosis. (Review) Clin. Chest. Med. 10: 341.
3. 3. Goble M. 1986. Drug-resistant tuberculosis. Semin. Respir. Infect. 1: 220.
4. 4. Frieden T R, Sterling T, Pablos-Mendez A, Kilburn J O, Cauthen G M, Dooley S W. 1993. The emergence of drug-resistant tuberculosis in New York City. N. Engl. J. Med. 328: 521.
5. 5. Girling D J. 1982. Adverse effects of antituberculosis drugs. Drugs 23: 56.
6. 6. Condos R, Rom W N, Schluger N W. 1997. Treatment of multidrug-resistant pulmonary tuberculosis with interferon-gamma via aerosol. Lancet 349: 1513.
7. 7. Giosuè S, Casarini M, Ameglio F, Alemanno L, Saltini C, Bisetti A. 1996. Minimal dose of aerosolized interferon-α in human subjects: biological consequences and side-effects. Eur. Respir. J. 9: 42.
8. 8. Giosuè S, Casarini M, Alemanno L, Galluccio G, Mattia P, Pedicelli G, Rebek L, Bisetti A, Ameglio F. 1998. Effects of aerosolized interferon-α in patients with pulmonary tuberculosis. Am. J. Respir. Crit. Care Med. 158: 1156.
9. 9. Casarini M, Ameglio F, Alemanno L, Zangrilli P, Mattia P, Paone G, Bisetti A, Giosuè S. 1999. Cytokine levels correlate with a radiologic score in active pulmonary tuberculosis. Am. J. Respir. Crit. Care Med. 159: 143.
10. 10. Giosuè S, Casarini M, Iorio M C, Mattia P, Bisetti A, Ameglio F. 1997. Inverse correlation between the number of mycobacteria detectable in sputum and levels of IFN-alpha measured in BAL at the time of diagnosis of tuberculosis. Eur. Respir. J. 10: 268s (abstract).
11. 11. McClatchy J K. 1980. Antituberculous drugs: mechanisms of action, drug resistance, susceptibility testing and assays in biological fluids. In: Lorian V, ed. Antibiotics in Laboratory Medicine. Baltimore: Williams & Wilkins.
12. 12. Miorner H, Gebre N, Karlsson U, Jonsson G, Macaden R, Wolde A, Assefa A. 1994. Diagnosis of pulmonary tuberculosis. Lancet 344: 127.
13. 13. Rennard S I, Basset G, Lecossier D, O'Donnell K M, Pinkston P, Martin P G, Crystal R G. 1986. Estimation of volume of epithelial lining fluid recovered by lavage using urea as marker of dilution. J. Appl. Physiol. 60: 532.
14. + T cells. J. Exp. Med. 178: 1655.
15. 15. Romagnani S. 1992. Induction of Th1 and Th2 responses: a key role for the "natural" immune response? (Review) Immunol. Today 13: 379.
16. 16. Parronchi P, De Carli M, Manetti R, Simonelli C, Sampognaro S, Piccinni M P, Macchia D, Maggi E, Del Prete G, Romagnani S. 1992. IL-4 and IFN (alpha and gamma) exert opposite regulatory effects on the development of cytolytic potential by Th1 or Th2 human T cell clones. J. Immunol. 149: 2977.
17. 17. Gutterman JU. 1994. Cytokine therapeutics: lessons from interferon-alpha. (Review) Proc. Natl. Acad. Sci. USA 91: 1198.
18. 18. Somoskovi A, Zissel G, Zipfel P F, Ziegenhagen M W, Klaucke J, Haas H, Schlaak M, Muller-Quernheim J. 1999. Different cytokine patterns correlate with the extension of disease in pulmonary tuberculosis. Eur. Cytokine Netw. 10: 135.
19. 19. Schluger N W, Rom W N. 1998. The host immune response to tuberculosis. (Review) Am. J. Respir. Crit. Care Med. 157: 679.
20. 20. Condos R, Rom WN, Liu Y M, Schluger N W. 1998. Local immune responses correlate with presentation and outcome in tuberculosis. Am. J. Respir. Crit. Care Med. 157: 729.
21. 21. Erb K J, Kirman J, Delahunt B, Moll H, Le Gros G. 1999. Infection of mice with Mycobacterium bovis-BCG induces both Th1 and Th2 immune responses in the absence of interferon-gamma signalling. Eur. Cytokine Netw. 10: 147.
22. 22. Bocci V. 1992. Physicochemical and biologic properties of interferons and their potential uses in drug delivery systems. (Review) Crit. Rev. Ther. Drug Carrier Syst. 9: 91.